EUVIMEDEUVIMED entdecken
Crossref

Matrix Matters: Head‐To‐Head Concordance of Serum and Plasma for NULISAseq CNS Disease Panel

Tommaso Merati iD, Chiara Tolassi iD, Alessandro Rondina, Irene Girotto iD, Marianna Bertoni, Eileen Mac Sweeney iD, Andrea Toja, Eqrem Rusi, Caterina Martinuzzo, Andrea Pilotto iD, Alessandro Padovani iD

Journal of Neurochemistry · 2026-11 · 170 (11)

DOI: 10.1111/jnc.70574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurochemistry, online erschienen am 05.11.2026. Verfasst von Tommaso Merati und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy. Hauptthemen laut MEDLINE: Proteomics, Neurodegenerative Diseases, Demyelinating Diseases. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Ministero dell'Istruzione, dell'Università e della Ricerca, European Commission, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blood‐based proteomic profiling is now widely applied in neurodegenerative and neuroinflammatory disease, yet the choice between serum and plasma remains poorly characterised for high‐multiplex platforms. Many biobanks consist predominantly of serum, whereas most current NUcleic‐acid‐Linked Immuno‐Sandwich Assay (NULISA) studies use plasma. We compared the 130‐protein NULISAseq central nervous system (CNS) Disease Panel head‐to‐head in matched serum and plasma collected at the same venipuncture from 62 participants (30 neurodegenerative, 19 demyelinating, 13 healthy controls). Agreement was measured with Spearman correlation (rho), Lin's concordance correlation coefficient (CCC), the intraclass correlation coefficient (ICC) and the mean paired plasma‐minus‐serum difference (dNPQ). Concordance was moderate to high: 114 of 130 proteins reached FDR significance and 18 reached rho ≥ 0.90, with a median rho of 0.65 (range 0.010–0.988). Proteins were classified into three concordance tiers (31, 6 and 30 proteins), with the remaining 63 showing intermediate concordance. Cytoskeletal markers (NEFH rho = 0.988; NEFL rho = 0.947) and glial GFAP (rho = 0.949, |dNPQ| < 0.5) were interchangeable between matrices. Phosphorylated tau (pTau) species retained excellent rank concordance but showed a systematic plasma‐greater‐than‐serum offset (pTau‐181 rho = 0.869, dNPQ = +0.67; pTau‐217 rho = 0.846, dNPQ = +0.64; pTau‐231 rho = 0.885, dNPQ = +0.89). Platelet‐derived analytes (CD40LG rho = 0.102, dNPQ = −4.74; BDNF rho = 0.223, dNPQ = −2.69) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) diverged markedly. For most clinically relevant neurodegeneration markers, especially cytoskeletal and glial proteins, serum is a valid substitute for plasma; absolute thresholds for phosphorylated tau require matrix‐specific calibration, whereas amyloid peptides and platelet‐sensitive analytes cannot be reliably compared across matrices without strictly standardised pre‐analytical conditions. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsNeurodegenerative DiseasesDemyelinating DiseasesHumansBiomarkersFemaleMaleMiddle Agedtau ProteinsAged

Stichwörter der Autor:innen

NULISAblood‐based biomarkersconcordanceneurodegenerationneurofilamentphosphorylated tauplasmaproteomicsserum

Substanzen

Biomarkerstau Proteins

Autor:innen und Institutionen

  • Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.
  • Neurology Unit, ASST Spedali Civili Brescia University Hospital, Brescia, Italy.
  • Neurobiorepository and Laboratory of Advanced Biological Markers, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
  • Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
  • Brain Health Center, University of Brescia, Brescia, Italy.

ORCID-Profile: Tommaso Merati, Chiara Tolassi, Irene Girotto, Eileen Mac Sweeney, Andrea Pilotto, Alessandro Padovani

Förderung

  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • European Commission
  • Ministero della Salute

Zitieren

APA

Merati, T., Tolassi, C., Rondina, A., Girotto, I., Bertoni, M., Sweeney, E. M., Toja, A., Rusi, E., Martinuzzo, C., Pilotto, A., & Padovani, A. (2026). Matrix Matters: Head‐To‐Head Concordance of Serum and Plasma for NULISAseq CNS Disease Panel. Journal of Neurochemistry, 170(11). https://doi.org/10.1111/jnc.70574

Vancouver

Merati T, Tolassi C, Rondina A, Girotto I, Bertoni M, Sweeney EM, et al. Matrix Matters: Head‐To‐Head Concordance of Serum and Plasma for NULISAseq CNS Disease Panel. Journal of Neurochemistry. 2026;170(11). doi:10.1111/jnc.70574

BibTeX
@article{Merati2026,
  author = {Merati, Tommaso and Tolassi, Chiara and Rondina, Alessandro and Girotto, Irene and Bertoni, Marianna and Sweeney, Eileen Mac and Toja, Andrea and Rusi, Eqrem and Martinuzzo, Caterina and Pilotto, Andrea and Padovani, Alessandro},
  title = {Matrix Matters: Head‐To‐Head Concordance of Serum and Plasma for NULISAseq CNS Disease Panel},
  journal = {Journal of Neurochemistry},
  year = {2026},
  volume = {170},
  number = {11},
  doi = {10.1111/jnc.70574}
}
Kostenlos starten →